As part of a strategic restructuring that includes deprioritizing its chronic granulomatous disease (CGD) programs, Prime Medicine is cutting about 25% of its staff and saying goodbye to its CEO, who resigned, the company announced May 19. The Cambridge, Massachusetts–based biotech had 214 full-time employees as of Dec. 31, 2024, according to an SEC filing, meaning the layoffs could affect about 54 people.
